Table 2.
Patient Disease history of AML – WHO classification by dose group of panobinostat (PAN).
| Disease history of AML WHO class (initial diagnosis), n (%) |
PAN 15 mg n = 11 | PAN 20 mg n = 15 | PAN 25 mg n = 8 | PAN 20 mg (expansion phase) n = 12 | All patients n = 46 |
|---|---|---|---|---|---|
| AML with recurrent genetic abnormalities | 0 (0.0) | 0 (0.0) | 1 (12.5) | 0 (0.0) | 1 (2.2) |
| AML with t(9;11)(p22;q23);(MLLT3-MLL) | 0 (0.0) | 0 (0.0) | 1 (12.5) | 0 (0.0) | 1 (2.2) |
| AML with multi-lineage dysplasia | 2 (18.2) | 4 (26.7) | 3 (37.5) | 3 (25.0) | 12 (26.1) |
| Without antecedent MDS or MDS/MPD, but with dysplasia in at least 50% of cells | 1 (9.1) | 3 (20.0) | 1 (12.5) | 3 (25.0) | 8 (17.4) |
| Evolving from MDS or MDS/MPD | 1 (9.1) | 1 (6.7) | 2 (25.0) | 0 (0.0) | 4 (8.7) |
| AML, not otherwise specified | 7 (63.6) | 10 (66.7) | 4 (50.0) | 9 (75.0) | 30 (65.2) |
| AML with minimal differentiation | 1 (9.1) | 1 (6.7) | 1 (12.5) | 2 (16.7) | 5 (10.9) |
| AML with maturation | 2 (18.2) | 5 (33.3) | 1 (12.5) | 2 (16.7) | 10 (21.7) |
| Acute myelomonocytic leukemia | 1 (9.1) | 2 (13.3) | 0 (0.0) | 0 (0.0) | 3 (6.5) |
| Acute monoblastic/monocytic leukemia | 2 (18.2) | 0 (0.0) | 1 (12.5) | 1 (8.3) | 4 (8.7) |
| Acute erythroid leukemia | 1 (9.1) | 1 (6.7) | 0 (0.0) | 3 (25.0) | 5 (10.9) |
| Others | 0 (0.0) | 1 (6.7) | 1 (12.5) | 1 (8.3) | 3 (6.5) |
| Unknown | 1 (9.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.2) |
Abbreviations: AHD antecedent hematologic disorders, AML acute myeloid leukemia, MDS myelodysplasia, MLL mixed lineage leukemia, MPD myeloproliferative disorders, WHO World Health Organization.